

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 November 2017 (30.11.2017)



(10) International Publication Number
WO 2017/202817 A1

(51) International Patent Classification:

C07D 487/08 (2006.01) A61P 29/00 (2006.01)
A61K 31/498 (2006.01) A61P 35/00 (2006.01)
A61P 15/00 (2006.01)

(21) International Application Number:

PCT/EP2017/062359

(22) International Filing Date:

23 May 2017 (23.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16171538.8 26 May 2016 (26.05.2016) EP
16178891.4 11 July 2016 (11.07.2016) EP

(71) Applicant: BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors: KOPPITZ, Marcus; Elsenbruchstraße 34A, 13467 Berlin (DE). SIEBENEICHER, Holger; Kruppstrasse 18, 10557 Berlin (DE). STEUBER, Holger; Hannoverische Strasse 19a, 10115 Berlin (DE). TER LAAK, Antonius; Hedwigstrasse 11, 12159 Berlin (DE). NUBBE-MEYER, Reinhard; Moorweg 96, 13509 Berlin (DE). ROTTMANN, Antje; Schneehornpfad 11A, 13089 Berlin (DE). IRLBACHER, Horst; Winsstrasse 47, 10405 Berlin (DE). BADER, Benjamin; Hillmannstrasse 14, 13467 Berlin (DE). PETERS, Michael; Heinrich-Roller Strasse 1, 10405 Berlin (DE). WAGENFELD, Andrea; Weddingenweg 64, 12205 Berlin (DE). TEREBESTI, Ildiko; Reichensteiner Weg 5, 14195 Berlin (DE).

(74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,

SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL] (1H-1,2,3-TRIAZOL-4-YL)METHANONES



(I)

(57) Abstract: The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I) in which R¹, R², R³, R⁴ and R⁵ are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.



WO 2017/202817 A1